We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple Cytogenetic Method Could Improve Classification of ALL Subtypes

By LabMedica International staff writers
Posted on 03 Jun 2026

Many cancers deviate from the normal chromosome number, but the clinical impact of extreme chromosome loss remains unclear. More...

This widespread genomic disruption is associated with aggressive disease and poorer outcomes, complicating diagnosis and treatment decisions. For diagnostic laboratories, a persistent challenge is distinguishing biologically distinct leukemias that appear similar on routine testing. Researchers now report pan-cancer evidence for hypodiploidy and introduce a simple cytogenetic method to separate look-alike acute lymphoblastic leukemia (ALL) subtypes.

Trinity College Dublin investigators published the study in Genome Medicine after analyzing genome data from more than 17,000 tumors across 34 cancer types, representing the first large-scale, pan-cancer investigation of extreme chromosome loss (hypodiploidy). Extensive chromosome loss proved more widespread than previously appreciated and was frequently linked to highly unstable tumors that are harder to treat. Instability was observed at multiple scales, from small gene alterations to whole-genome doubling, and hypodiploid tumors tolerated and continued to evolve despite profound genomic disruption.

The research team identified a subset of cancers—including ALL, kidney chromophobe cancer, and adrenocortical carcinoma—that maintain stable, “stereotyped” chromosome-loss patterns over time. These consistent profiles contrasted with other hypodiploid tumors marked by pronounced genomic instability. The stereotyped patterns formed the basis for the ALL classification approach described.

The investigators also developed a simple method to distinguish two forms of ALL that can appear nearly identical under the microscope but have very different prognoses. The approach uses recurring chromosome-loss patterns detectable with routine laboratory cytogenetic data. By leveraging these stereotyped karyotypic features, the method is intended to support more accurate patient classification while minimizing both misclassification of aggressive disease and overtreatment of lower-risk cases.

Collectively, the results support a unifying principle: tumors with very different karyotypes—from extreme chromosome gain to extreme loss—can behave similarly when they share high levels of chromosomal instability. In these cancers, it is the instability itself, rather than any specific pattern of chromosome change, that appears to drive disease progression.

“Our findings could have important implications for diagnosis and patient care,” said Dr. Máire Ní Leathlobhair, senior author of the research, from Trinity’s School of Genetics and Microbiology. "One thing we focused on was leukemias that can appear very similar in routine chromosome testing but have very different outcomes for patients. By developing a simple way to distinguish these cases using cytogenetic data, our work could help doctors identify high-risk patients earlier and avoid misclassifying aggressive cancers as lower-risk disease or treating lower-risk forms overly aggressively."

“The study also strengthens the growing idea that chromosomal instability itself, the ongoing chaos and reshuffling inside cancer genomes, may be one of the key drivers of cancer aggressiveness. That matters because it shifts the focus away from individual mutations alone and toward the broader instability of the cancer genome. In practical terms, this could influence how future cancer therapies are designed and which patients are selected for particular treatments,” said Elle Loughran, lead author from Trinity College Dublin.

Related Links
Trinity College Dublin


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.